Temozolomide (TMZ) is an imidazotetrazine prodrug used to treat glioblastoma multiforme.
Its physicochemical properties and small size confer the ability to cross the blood-brain …

In the era of precision medicine, there is increasing evidence that conventional cytotoxic
agents may be suitable candidates for therapeutic drug monitoring (TDM)-guided drug …

Purpose: Preclinical data showed that prophylactic, low-dose temozolomide (TMZ)
significantly prevented breast cancer brain metastasis. We present results of a phase I trial …

The alkylating agent temozolomide (TMZ) is the first-line chemotherapeutic for glioblastoma
(GBM), a common and aggressive primary brain tumor in adults. However, its poor stability …

We report a rapid and sensitive LC-MS/MS method that allows the simultaneous detection of
68 commonly prescribed antidepressants, benzodiazepines, neuroleptics, and metabolites …

Using green and high efficient solvents to extract and trace active ingredients of traditional
Chinese medicine (TCM) in the complex biological samples was still challenging. In this …

Background: Temozolomide (TMZ) oral suspension (Ped-TMZ, KIZFIZO®) is being
developed for the treatment of relapsed or refractory neuroblastoma, a rare cancer affecting …

Novel disposable screen-printed electrodes modified with silicon dioxide nanoparticles were
developed for the electrochemical determination of temozolomide and its interaction with …

Sunitinib is a multi-targeted tyrosine kinase inhibitor approved for the treatment of renal cell
carcinoma and imatinib-resistant gastrointestinal stromal tumor and is currently being …

Background: Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma.
However, the pharmacokinetics of TMZ to establish a treatment strategy for patients …